Delivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, ...
The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) ...
As molecule complexity rises, advanced cell line development platforms are giving biopharma companies new tools to overcome ...
"This year's Late-Breaking Science program reflects the pace of innovation transforming heart failure care," said Jennifer ...
This announcement describes preparation of a demonstration and does not constitute a commercial contract award. Medical Care ...
FAYUVI™ is the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator® Platform process. Its commercial ...
Established in 1919 by Lee Bidgood and currently led by Dean Kay Palan, the Culverhouse College of Business at The University ...
NurExone’s participation across the four events comes as the Company continues to advance its lead therapeutic candidate, ...
Silo’s biopharmaceutical intellectual property portfolio currently holds numerous issued and allowed patents. About Silo ...
BioCytics, Inc., has engaged Eremid® Genomic Services to help sequence an autologous immune cell fraction that is the leading ...
Dawson James Securities, Inc. is acting as sole placement agent for the offering.
Newly permanent CBER and CDER directors Karim Mikhail and Michael Davis are widely expected to continue the FDA’s efforts toward an adaptive framework for rare disease therapies. If approved by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results